<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20181126041763N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-01-18</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of flatulent carbohydrates restricted diet on gut microbium and inflammation in patients with ulcerative colitis</public_title>
      <acronym>FODMAP</acronym>
      <scientific_title>Effect of fermentable carbohydrates restricted diet on gut microbium and some inflammatory indices in patients with ulcerative colitis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>32</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/35509</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: participants will be matched in terms of age (20 to 40 and 40 to 60 years), gender (male/female), body mass index (18.5 to 24.9 and 25 to 30) and drug type (anti-inflammatory (steroidal/anti-TNF) and immunosuppressant) in blocks composed of two patients in each blocks. Then, participants in each block will be randomly allocated to intervention or control groups. In order to randomize assignment of participants, each person will be given a specific code. Then, a person outside the study will be asked to draw the code out of a pot using the lottery. Participant with the first draw out code will be allocated to the intervention group, and the second code as the control; in order the rest of participants will be randomly assigned to the two groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Inflammatory Bowel Disease (Ulcerative Colitis).</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Low-FODMAP diet in addition to general recommendations for IBD patients. Firstly, the basal metabolic rate (BMR) of the patients will be calculated using their age, sex, height and weight by the Harris Benedict formula. Then, daily energy requirement of each individual is calculated based on his/her physical activity when considering the thermogenic effect of foods (TEF). The macronutrient composition of this diet includes 55% energy from carbohydrates, 25% from fats, and 20% from proteins. Then, required values ​​from each food group will be calculated. In each food group, food items with high FODMAP will be discarded, and the remaining foods will be divided into 6 meals/day, including 3 main meals and 3 snacks. Accordingly, a two-week meal menu will be set up that patients will continue it for two additional weeks (a total of 4 weeks). Intervention 2: Control group: General recommendations for patients with IBD including recommendations to have physical activity, timely disposing of feces, consumption of low-fat dairies and meats, consumption of vegetable oils, and reduction in consumption of refined sugars.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is No additional information are available</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Alireza Milajerdi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Enghelab street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>14155-6559</zip>
        <telephone>+98 21 8889 6696</telephone>
        <email>amkhv@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ahmad Esmaillzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nutritional Sciences and dietetics, Hojatdoost Ave., Naderi street, Keshavarz Blv, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>14155-6559</zip>
        <telephone>+98 21 8895 5805</telephone>
        <email>a.esmaillzadeh@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age over than 20 and under 60 years
Moderate ulcerative colitis (ulcerative colitis diagnosis will be done by a gastroenterologist, using the Mayo score) who are on stable drug therapy. The scores of 6-8 will be considered as moderate UC.
BMI 18.5 to 30 kg/m2</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Changed in the type or dosage of their drugs over the past month
Suffered from other gastrointestinal diseases including cancers and infectious diseases
Pregnant or breastfeeding women or those with a decision for pregnancy in the near future
Use of antibiotics
Consumed pre- or pro-biotic products during the last two months
Use tobacco or smoke
Hospitalized in the last three months
Infection over the past 3 months
Suffering from any inflammation-promoting condition
Used multi-vitamin and mineral supplements during the past month</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K51</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Ulcerative colitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Low-FODMAP diet in addition to general recommendations for IBD patients. Firstly, the basal metabolic rate (BMR) of the patients will be calculated using their age, sex, height and weight by the Harris Benedict formula. Then, daily energy requirement of each individual is calculated based on his/her physical activity when considering the thermogenic effect of foods (TEF). The macronutrient composition of this diet includes 55% energy from carbohydrates, 25% from fats, and 20% from proteins. Then, required values ​​from each food group will be calculated. In each food group, food items with high FODMAP will be discarded, and the remaining foods will be divided into 6 meals/day, including 3 main meals and 3 snacks. Accordingly, a two-week meal menu will be set up that patients will continue it for two additional weeks (a total of 4 weeks).</i_keyword>
      <i_keyword>Control group: General recommendations for patients with IBD including recommendations to have physical activity, timely disposing of feces, consumption of low-fat dairies and meats, consumption of vegetable oils, and reduction in consumption of refined sugars</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Gut microbiota. Timepoint: Before Intervention and 4 weeks later. Method of measurement: PCR Method.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Inflammation. Timepoint: Before intervention and 4 weeks later. Method of measurement: ELISA kit.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-10-03</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>School of nutritional sciences and dietetics, Hojatdoost Ave., Naderi street, Keshavarz blv, Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
